Value Creation through Company Building
We invest in growth – creating leading international companies in their field. EEP understand that creating value takes time and capital – that is why we are dedicated to sustainable company building.
LIFE SCIENCE PORTFOLIO
Azanta is a Danish specialty pharma company operating within oncology, women´s health and addiction medicine.
Azanta is a specialty pharma company focused on women’s health and addiction medicine. The Company also has a program within oncology.
Azanta has its own sales organization supported by in-house medical and regulatory departments and a logistics infrastructure. The Company’s sales force operates in the Nordic countries and in France and currently works through partners in other territories. Azanta seeks to be an international market leader within certain specialty pharma product categories, particularly in women’s health, employing innovative repositioning and drug formulation strategies.
Following EEP’s investment in 2015, Azanta has had the opportunity to strengthen its organization and expand its commercial infrastructure. Also, the Company has been successful in securing regulatory approval of Angusta®; a best in class labor induction medicine product. Further, the Company has realized significant top-line growth and strengthen its balance sheet.
CMC Biologics is a leading International Biologics Contract & Development Manufacturing …
CMC Biologics, now rebranded as AGC Biologics, is a leading international Contract Development and Manufacturing Organization (“CDMO”) offering process development and manufacture of biopharmaceutical Active Pharmaceutical Ingredient (“API”).
During EEP’s ownership the Company established its first laboratories and built its first integrated manufacturing facility in Copenhagen, Denmark and thereafter acquired two manufacturing facilities in the US.
The Company’s services include process development, scale-up, and production of API protein material for pre-clinical, phase I, II, III and in-market commercial quantities.
The Company is approved for commercial production by FDA, EMEA, Health Canada and the Japanese Health Authorities. Over the years the Company has developed a large diversified client base of biopharmaceutical companies including several of the world’s largest pharma companies.
Since EEP invested in 2002 and until the sale to AGC Japan in 2017, the Company realised an average annual revenue growth rate in excess of 50% and the number of staff grew from 6 to in excess of 500.
As an active lead investor, EEP assisted management and the Company in realising this expansion by ensuring adequate equity and debt funding, as well as being a partner in crafting successful strategies and building a winning organisation. Further, EEP had a lead role in planning and negotiating the sale of the Company to the best strategic buyer for the business.
Aster-Cephac is a leading European multi-service Life Sciences Contract Research Organization…
Aster-Cephac, now re-branded as SGS Life Sciences, is a leading European multi-service Life Sciences Contract Research Organization (“CRO”) dedicated to early Clinical Development and Bio-analysis services.
The Company offers Clinical Pharmacology (Phase I & II studies), Bio-analysis, Bio-statistic and Medical writing services to the world’s pharmaceutical industries and personal care companies.
During the time of investment (1996 – 2006) Aster-Cephac more than quadrupled its annual revenue and increased it profitability margins to be in line with other world-leading international CROs. As Chairman of the Board, David Kauffmann, was part of setting the Company’s strategic direction and establishing the priorities for building the Company’s organizational and business infrastructure to sustain and accelerate the Company’s growth.
The global CRO industry had been consolidating over several years and the sale of Aster-Cephac to the SGS Life Sciences was planned and realized considering this market dynamic.
Bio-Research Laboratories, now rebranded as Charles River Laboratories, is a world leading pre-clinical research organization.
Bio-Research Laboratories (“Bio-Research”), now rebranded as Charles River Laboratories, is a world leading pre-clinical research organization. The Company, is one of the corner-stone operational units in the Charles River Group, offering pre-clinical drug development services to the world’s pharmaceutical and biotechnology industries.
The Company was originally formed as part of the Canadian Crown corporation biosciences group. When taken private Bio-Research was looking for growth capital which could assist the Company with its international growth aspirations.
During the investment period (1992 – 1996) Bio-Research more than doubled its revenue and turned from being loss-making to becoming very profitable and cash generative. The Company placed a renewed emphasis on marketing of new, higher margin service lines and broadening its client base to become more international.
Throughout the duration of the investment, discussions were held with industry players and in doing so many partners and potential purchaser of the Company were identified. In 1996, Bio-Research was sold to ClinTrials Research Inc, which later was acquired by Inveresk Research Group, now part of the Charles River Laboratories group.
PharmaKinetics Laboratories Inc., sold to Bioanalytical Systems Inc., was a Baltimore - US based, Contract Research…
PharmaKinetics Laboratories Inc. (“PharmaKinetics”), sold to Bioanalytical Systems Inc. (“BASi”), was a Baltimore, US based, Contract Research organization (“CRO”) providing pharmacology and bioanalysis services to the generic pharmaceutical industry.
During the investment period the Company’s management and quality systems were upgraded in order to accommodate the standards required by the US Food and Drug Administration (“FDA”) and the pharmaceutical client base. In 2002 the Company was sold to BASi.
"EEP was critical for CMC Biologics in the successful transition from start-up to a multinational leading biologics CDMO with revenues in excess of $150 million."
Founder of CMC Biologics
Transmode, now part of Infinera, provides leading optical networking solutions for transport of data, voice and video traffic…
Transmode, now part of Infinera, provides leading optical networking solutions for transport of data, voice and video traffic, based on CWDM and DWDM technology (Coarse/Dense Wavelength Division Multiplexing).
EEP invested in the Company in 2000 and was the first external investor. At the time Transmode was a start-up operation with an interesting technology and a promising and documented business model. EEP worked with the Company for 12 years to build an award-winning company, generating 2011 revenue in excess of Euro 100 million. The Company successfully completed its Initial Public Offering (“IPO”) on NASDAQ OMX Stockholm in May 2011 with a market capitalisation of around Euro 200 million.
Transmode’s unique Intelligent WDM (iWDM) approach has led to widespread deployment of systems in a wide customer base consisting of fixed and mobile network operators, service providers, large enterprises and public institutions across Europe, the Americas and Asia.
At the IPO, EEP realised part of its investment and completed a full exit over the following 2 years. In 2015 the Company was acquired by Infinera.
Whatsonwhen ("WoW"), now part of Alphabet, is a leading independent multi-platform publishing business specialised…
Whatsonwhen (“WoW”), now part of Alphabet Inc., is a leading independent multi-platform publishing business specialised in time and location specific leisure, entertainment and professional events content for businesses and consumers.
The Company sells factual and editorial content primarily to travel companies, carriers, portals, mobile operators, ISPs and travel guide companies. WoW licenses its content through co-branded hosted solutions or XML feeds across all platforms (e.g. interactive TV, wireless, internet, print, and video) to its clients. The business model includes revenue generation from (i) licensing of proprietary content, (ii) providing bespoke written content, and (iii) provisioning of technical and event-related consultancy.
EEP provided both equity and convertible debt funding to the Company to allow it to implement and perfect the business model and grow the business. EEP also assisted the Company in building the organisation, strengthening the management and developing the financial systems.
WoW was founded in May 1999. EEP first invested in 2000 and the Company was successfully sold to US publishing group John Wiley & Sons Inc. in October 2006. The Company is now a part of Alphabet Inc.
Prenax provide fully integrated IT interphase administration services of acquisition, access and management…
Prenax provide fully integrated IT interphase administration services of acquisition, access and management of all print and online information. The service covers journals, newspapers, databases, memberships and books.
Starting with just one client in Stockholm, Prenax has grown to be the world’s largest corporate subscription management partner to organizations in the USA, Europe and Asia-Pacific. Clients include service industries, advanced engineering, consulting, medical libraries, pharmaceutical groups and local government.
Prenax clients have a great need for a wide variety of publications and have demands for rapid responses and attention to detail, making the administration regarding subscriptions quite considerable. By taking complete responsibility for the administrative tasks related to subscriptions, Prenax saves its customers time and money.
The Company was established in 1991 and EEP first invested in 2000. It is headquartered in Sweden and now also has offices in the United Kingdom, France, Norway, Australia and the USA. Today Prenax manages 250,000 subscriptions for over 4,000 customers. Turnover exceeds $150 million. Prenax was sold in a secondary Management Buyout in April 2012.
"When building and growing a business it is important to have a shareholder who understands the challenges and can support the Company in that process. EEP proved to be a great shareholder on this journey which led to a successful exit"